Centocor Inc. reported positive study results of tests using its drug Remicade in patients suffering from psoriasis.
The results of the phase-III study were presented by the Horsham, Pa., biotechnology company Friday at the annual American Academy of Dermatology meeting in San Francisco.
The study showed patients taking Remicade for 10 weeks achieved at least 75 percent improvement in their psoriasis, a chronic inflammatory disease. Nearly 2 million Americans suffer from the skin disorder.
Remicade is already approved as a treatment for rheumatoid arthritis and Crohn's disease.
The Food and Drug Administration is reviewing Centocor's application, filed in November, to expand the use of the drug to include treating moderate to severe psoriasis
